Table 4.
Measures of plasma systemic inflammation.
| Measure | ET | P-SIT | A-SIT | CON |
|---|---|---|---|---|
| CRP (mg·L−1) | ||||
| Pre | 2.8 ± 1.6 | 2.7 ± 1.3 | 2.1 ± 1.4 | 2.1 ± 1.5 |
| Post | 2.9 ± 1.6 | 2.1 ± 0.9 | 1.9 ± 1.2 | 2.1 ± 1.6 |
| Raw Δ | 0.2 ± 1.2 | −0.6 ± 1.0 | −0.2 ± 0.9 | 0.0 ± 0.9 |
| % Δ | 11.8 ± 40.9 | −12.3 ± 50.7 | −1.5 ± 34.6 | 24.3 ± 118.5 |
| IL-6 (pg·L−1) | ||||
| Pre | 3.16 ± 1.36 | 3.11 ± 1.04 | 3.29 ± 0.53 | 3.27 ± 0.64 |
| Post | 3.55 ± 0.75 | 3.18 ± 0.63 | 3.57 ± 0.38 | 3.65 ± 0.81 |
| Raw Δ | 0.40 ± 1.03 | 0.08 ± 1.01 | 0.28 ± 0.46 | 0.37 ± 0.77 |
| % Δ | 22.8 ± 30.6 | 10.9 ± 35.5 | 10.1 ± 14.0 | 12.9 ± 23.2 |
| TNF-α (pg·L−1) | ||||
| Pre | 6.1 ± 1.7 | 6.8 ± 1.5 | 6.6 ± 1.8 | 5.2 ± 1.4 |
| Post | 6.8 ± 2.1 | 6.6 ± 1.9 | 6.4 ± 1.9 | 5.7 ± 1.3 |
| Raw Δ | 0.7 ± 1.6 | −0.2 ± 2.2 | −0.2 ± 1.3 | 0.5 ± 1.5 |
| % Δ | 13.7 ± 28.8 | 1.3 ± 31.9 | −1.6 ± 23.1 | 16.0 ± 33.5 |
| MCP-1 (pg·L−1) | ||||
| Pre | 121 ± 43 | 137 ± 43 | 145 ± 46 | 111 ± 86 |
| Post | 121 ± 38 | 129 ± 33 | 141 ± 43.02 | 109 ± 84 |
| Raw Δ | −0.2 ± 33.0 | −7.5 ± 43.3 | −4.1 ± 34.1 | −1.8 ± 61.6 |
| % Δ | 7.7 ± 37.9 | 4.0 ± 41.0 | 3.1 ± 28.8 | 25.8 ± 92.2 |
| IL-10 (pg·L−1) | ||||
| Pre | 3.72 ± 2.78 | 3.77 ± 3.03 | 3.32 ± 2.32 | 4.98 ± 2.40 |
| Post | 5.31 ± 5.25 | 5.77 ± 4.59 | 2.93 ± 1.47 | 5.35 ± 3.17 |
| Raw Δ | 1.59 ± 3.72 | 2.00 ± 4.08 | −0.39 ± 2.00 | 0.38 ± 1.97 |
| % Δ | 53.2 ± 85.2 | 118.0 ± 218.3 | 16.7 ± 84.5 | 8.8 ± 42.6 |
Data are mean ± standard deviation. ET: endurance training exercise group, n = 15; P-SIT: passive sprint-interval training exercise group, n = 15; A-SIT: active sprint-interval training exercise group, n = 15; CON: control group, n = 14. CRP: C-reactive protein; IL-6: interleukin 6; TNFα: tumor necrosis factor α; MCP-1: monocyte chemoattractant protein 1; IL-10: interleukin 10. There were no significant pre-to-post or between-condition differences in plasma CRP and cytokine measures after the study interventions (P > 0.05).